Abstrakt

An overview of Menopausal Hormone Replacement Therapy (MHRT)

Mamatha M

Menopausal hormone therapy has been challenging for contributors in care of menopausal women. Important variables which affects the balance of benefit-risk profile are age and years. Many hormone products were approved for use in menopausal hormone therapy according to U.S. Food and Drug Administration (FDA). FDA-approved products have subjected to extensive testing and are mainly produced under standardized conditions to shield that each and every dose—whether in a pill, a skin patch, or a cream must contains the correct amount of the suitable hormones. Hormone replacement therapy around the time of menopause can reduce the risk of developing diabetes in women. HRT can also prevent the loss of bone density. The duration of combined therapy is preferably limited to not more than 5 years due to the lack of first-pass metabolic effects, which in turn mainly evade of increased synthesis of clotting proteins by liver, triglycerides, C-reactive proteins and sex hormone-binding globulin.